Bivalirudin: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Gerald Chi (talk | contribs)
CMEAdmin, Bureaucrats, bureaucrats, editnews, exportpages, interwiki, nocaptcha, nukepages, smwadministrator, Administrators, Widget editors
17,702 edits
m Changed protection level for "Bivalirudin" ([Edit=Allow only autoconfirmed users] (expires 23:54, 12 February 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 23:54, 12 February 2014 (UTC)))
Jesus Hernandez (talk | contribs)
nocaptcha
4,185 edits
No edit summary
Line 1: Line 1:
<small>'''''Brand Names / Synonyms:''''' Angiomax, Angiox </small>
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
 
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Bivalirudin|{{fontcolor|#6C7B8B|Bivalirudin}}]]'''''
<font size="4">
|-
==Dosing and Administration==
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ANGIOMAX<sup>®</sup> FDA Package Insert
'''PCI/PCTA
|-
Adults'''
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin indications and usage|Indications and Usage]]
 
|-
IV Bolus dose of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h for duration of PCI procedure. Five minutes after bolus dose, obtain ACT and administer additional bolus of 0.3 mg/kg if indicated.
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin dosage and administration|Dosage and Administration]]
 
|-
'''HIT/HITTS
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin dosage forms and strengths|Dosage Forms and Strengths]]
Adults'''
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin contraindications|Contraindications]]
IV Bolus dose of 0.75 mg/kg, followed by a continuous infusion at a rate of 1.75 mg/kg/h for the duration of the procedure.
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin warnings and precautions|Warnings and Precautions]]
'''Continuation of Therapy
|-
Adults'''
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin adverse reactions|Adverse Reactions]]
 
|-
IV Infusion may be continued for up to 4 h post-procedure as indicated. After 4 h, an additional IV infusion of 0.2 mg/kg/h for up to 20 h may be given if needed.
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin drug interactions|Drug Interactions]]
 
|-
'''Concomitant Therapy
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin use in specific populations|Use in Specific Populations]]
Adults'''
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin overdosage|Overdosage]]
Bivalirudin is intended for concurrent use with aspirin (300 to 325 mg/day).
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin description|Description]]
'''Renal Function Impairment
|-
Adults'''
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin clinical pharmacology|Clinical Pharmacology]]
 
|-
IV Ccr 30 to 50 mL/min: Administer infusion at rate of 1.75 mg/kg/h. Ccr less than 30 mL/min: Reduce infusion rate to 1 mg/kg/h. Hemodialysis: Reduce infusion rate to 0.25 mg/kg/h. No reduction in bolus dose needed.
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin nonclinical toxicology|Nonclinical Toxicology]]
 
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin clinical studies|Clinical Studies]]
[[{{PAGENAME}}#FDA Package Insert Resources|FDA Package Insert Resources]]
|-
<br></font size><small>Indications, Contraindications, Side Effects, Drug Interactions, etc.</small><font size="4"><br>
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin how supplied storage and handling|How Supplied/Storage and Handling]]
<br>
|-
[[{{PAGENAME}}#Publication Resources|Publication Resources]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin patient counseling information|Patient Counseling Information]]
<br></font size><small>Recent articles, WikiDoc State of the Art Review, Textbook Information</small><font size="4"><br>
|-
<br>
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin labels and packages|Labels and Packages]]
[[{{PAGENAME}}#Trial Resources|Trial Resources]]
|-
<br></font size><small>Ongoing Trials, Trial Results</small><font size="4"><br>
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Bivalirudin
<br>
|-
[[{{PAGENAME}}#Guidelines & Evidence Based Medicine Resources|Guidelines & Evidence Based Medicine Resources]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov]
<br></font size><small>US National Guidelines, Cochrane Collaboration, etc.</small><font size="4"><br>
|-
<br>
|}
[[{{PAGENAME}}#Media Resources|Media Resources]]
<br></font size><small>Slides, Video, Images, MP3, Podcasts, etc.</small><font size="4"><br>
<br>
[[{{PAGENAME}}#Patient Resources|Patient Resources]]
<br></font size><small>Discussion Groups, Handouts, Blogs, News, etc.</small><font size="4"><br>
<br>
[[{{PAGENAME}}#International Resources|International Resources]]
<br></font size><small>en Español</small><font size="4"><br>
<br>
----
<br>
<br>
<br>
<br>
 
==FDA Package Insert Resources==
[[Bivalirudin mechanism of action | Mechanism of action]]
<br>
<br>
[[Bivalirudin indications|Indications]]
<br>
<br>
[[Bivalirudin contraindications|Contraindications]]
<br>
<br>
[[Bivalirudin side effects|Side Effects]]
<br>
<br>
[[Bivalirudin drug interactions|Drug Interactions]]
<br>
<br>
[[Bivalirudin precautions|Precautions]]
<br>
<br>
[[Bivalirudin overdose|Overdose]]
<br>
<br>
[[Bivalirudin instructions for administration|Instructions for Administration]]
<br>
<br>
[[Bivalirudin how supplied|How Supplied]]
<br>
<br>
[[Bivalirudin pharmacokinetics and molecular data|Pharmacokinetics and Molecular Data]]
<br>
<br>
[[Bivalirudin FDA package label|FDA label]]
<br>
<br>
[http://google2.fda.gov/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&x=0&y=0&client=FDA&site=FDA&lr=&proxystylesheet=FDA&output=xml_no_dtd&getfields=* FDA on {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>
 
==Publication Resources==
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Most Recent Articles on {{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}]
<br>
<br>
[http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}%20AND%20systematic%5Bsb%5D  Review Articles on {{PAGENAME}}]
<br>
<br>
[[WikiDoc state of the art review on bivalirudin|WikiDoc State of the Art Review]]
<br>
<br>
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+%28%28N+Engl+J+Med%5Bta%5D%29+OR+%28Lancet%5Bta%5D%29+OR+%28BMJ%5Bta%5D%29%29 Articles on {{PAGENAME}} in N Eng J Med, Lancet, BMJ]
<br>
<br>
[http://books.google.com/books?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=gp Textbook Information on {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>
==Trial Resources==
[http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Ongoing Trials with {{PAGENAME}} at Clinical Trials.gov]
<br>
<br>
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+%28randomized+controlled+trial%5BPublication+Type%5D+OR+%28randomized%5BTitle%2FAbstract%5D+AND+controlled%5BTitle%2FAbstract%5D+AND+trial%5BTitle%2FAbstract%5D%29%29 Trial Results with {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>
 
==Guidelines & Evidence Based Medicine Resources==
[http://www.guideline.gov/search/searchresults.aspx?Type=3&txtSearch={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&num=20 US National Guidelines Clearinghouse on {{PAGENAME}}]
<br>
<br>
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:({{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}) AND (Cochrane Database Syst Rev[ta])}} Cochrane Collaboration on {{PAGENAME}}]
<br>
<br>
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:({{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}) AND (Cost effectiveness)}} Cost Effectiveness of {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>
==Media Resources==
[http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+ppt&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a Powerpoint Slides on {{PAGENAME}}]
<br>
<br>
[http://images.google.com/images?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wi Images of {{PAGENAME}}]
<br>
<br>
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&hs=hPo&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+podcasts+OR+MP3&btnG=Search Podcasts & MP3s on {{PAGENAME}}]
<br>
<br>
[http://video.google.com/videosearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&um=1&sa=N&tab=fv# Videos on {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>
 
==Patient Resources==
[[Bivalirudin (patient information)|Patient Information from National Library of Medicine]]
<br>
<br>
[http://www.google.com/search?hl=en&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:for_patients&cx=disease_for_patients&sa=N&oi=cooptsr&resnum=0&ct=col3&cd=1  Patient Resources on {{PAGENAME}}]
<br>
<br>
[http://groups.google.com/groups/search?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search Discussion Groups on {{PAGENAME}}]
<br>
<br>
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla:en-US:official&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:patient_handouts&cx=disease_for_health_professionals&sa=N&oi=coopctx&resnum=0&ct=col1&cd=3 Patient Handouts on {{PAGENAME}}]
<br>
<br>
[http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]
<br>
<br>
[http://news.google.com/news?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wn {{PAGENAME}} in the News]
<br>
<br>
[http://finance.google.com/finance?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=te {{PAGENAME}} in the Marketplace]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>
==International Resources==
[http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+en+espanol&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a {{PAGENAME}} en Español]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>
</font size>
----
{{FDA}}
[[Category:Drugs]]

Revision as of 10:05, 10 March 2014

Bivalirudin
ANGIOMAX® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Bivalirudin
ClinicalTrials.gov
Retrieved from "https://www.wikidoc.org/index.php?title=Bivalirudin&oldid=952785"